Fluvoxamine: a $4 Antidepressant That Reduces COVID 19 Hospitalizations


MedCram – Medical Lectures Explained CLEARLY

Roger Seheult, MD of MedCram on how Fluvoxamine, an inexpensive SSRI medication FDA approved in 1994, was shown to reduce COVID 19 hospitalizations and deaths in a recent randomized placebo controlled trial published in the Lancet. Fluvoxamine (Luvox) was also compared to other medications such as ivermectin, metformin, and hydroxychloroquine in the trial.

Roger Seheult, MD is the co-founder and lead professor at https://www.medcram.com He is Board Certified in Internal Medicine, Pulmonary Disease, Critical Care, and Sleep Medicine and an Associate Professor at the University of California, Riverside School of Medicine.

(This video was recorded on November 1, 2021)


Fluvoxamine in the treatment of anxiety disorders (PMC) | https://www.ncbi.nlm.nih.gov/pmc/arti…

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial (Lancet) | https://www.thelancet.com/journals/la…